Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes

Prostate Cancer and Prostatic Diseases volume 18, pages 63–68 (2015)Cite this article

Subjects

Abstract

Background:

To determine the effect of statins and metformin in combination on biochemical recurrence (BCR) among diabetic men undergoing radical prostatectomy (RP).

Methods:

Diabetic men undergoing RP at our institution from January 1995 to March 2012 were retrospectively reviewed. Recipients of adjuvant radiation or hormonal therapy were excluded. Statin and/or metformin use was determined through review of electronic records. BCR-free survival was plotted using Kaplan–Meier analysis, and the effect of statins and metformin on BCR was assessed via a multivariate Cox proportional hazards model.

Results:

Seven hundred and sixty-seven men met the inclusion criteria. Seventy-six (9.9%) were users of statins only, 56 (7.3%) were users of metformin only and 42 (5.5%) were dual users. Median follow-up time was 27 months. Dual users were less likely than nonusers or users of either medication alone to have a biopsy Gleason sum of 8–10 (P=0.033), and tended towards a lower rate of pathological T stage of pT3 or higher (P=0.064). Dual users had the highest 2-year and 5-year BCR-free survival, although this was not statistically significant (P=0.205). On multivariate regression, neither statin nor metformin use alone was significantly associated with BCR-free survival. However, their interaction led to a significantly lower BCR risk than would be expected from each medication’s independent effects (hazard ratio=0.2; P=0.037).

Conclusions:

The combination of statins and metformin in men undergoing RP for prostate cancer (PCa) may be associated with a lower BCR risk than would be predicted based on the independent effects of both medications. A synergism between these two agents is biologically plausible based on our current understanding of their diverse molecular pathways of action. The results of future clinical trials involving the use of either medication in men with PCa should be carefully assessed for confirmatory evidence of such a relationship.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.

    Article  Google Scholar 

  2. Cooperberg MR, Broering JM, Carroll PR . Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117–1123.

    Article  Google Scholar 

  3. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012; 61: 664–675.

    Article  Google Scholar 

  4. Kattan MW, Vickers AJ, Yu C, Bianco FJ, Cronin AM, Eastham JA et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009; 115: 1005–1010.

    Article  Google Scholar 

  5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.

    Article  CAS  Google Scholar 

  6. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H . The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872–1876.

    Article  Google Scholar 

  7. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433–439.

    Article  CAS  Google Scholar 

  8. Chan KK, Oza AM, Siu LL . The statins as anticancer agents. Clin Cancer Res 2003; 9: 10–19.

    CAS  PubMed  Google Scholar 

  9. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T . Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 2011; 47: 819–830.

    Article  CAS  Google Scholar 

  10. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM . Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930–942.

    Article  CAS  Google Scholar 

  11. Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19: 722–728.

    Article  Google Scholar 

  12. Ben sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465–2475.

    Article  CAS  Google Scholar 

  13. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–10812.

    Article  CAS  Google Scholar 

  14. Ben sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576–3586.

    Article  CAS  Google Scholar 

  15. Flavin R, Zadra G, Loda M . Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 283–294.

    Article  CAS  Google Scholar 

  16. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013; 34: 2823–2832.

    Article  CAS  Google Scholar 

  17. Bansal D, Undela K, D'cruz S, Schifano F . Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.

    Article  CAS  Google Scholar 

  18. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389–3398.

    Article  CAS  Google Scholar 

  19. Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C . Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 2013; 90: 263–269.

    Article  CAS  Google Scholar 

  20. Nielsen SF, Nordestgaard BG, Bojesen SE . Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792–1802.

    Article  CAS  Google Scholar 

  21. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1427–1434.

    Article  CAS  Google Scholar 

  22. Zhang P, Li H, Tan X, Chen L, Wang S . Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013; 37: 207–218.

    Article  Google Scholar 

  23. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069–3075.

    Article  CAS  Google Scholar 

  24. Penney KL, Stampfer MJ . The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 2013; 31: 3054–3055.

    Article  CAS  Google Scholar 

  25. Lehman DM, Lorenzo C, Hernandez J, Wang CP . Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012; 35: 1002–1007.

    Article  CAS  Google Scholar 

  26. Ritch CR, Hruby G, Badani KK, Benson MC, Mckiernan JM . Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108: E211–E216.

    Article  Google Scholar 

  27. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ . The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511–1518.

    Article  CAS  Google Scholar 

  28. Hitron A, Adams V, Talbert J, Steinke D . The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012; 36: e243–e250.

    Article  CAS  Google Scholar 

  29. Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492–499.

    Article  Google Scholar 

  30. Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011; 27: 54–62.

    Article  CAS  Google Scholar 

  31. Woodard J, Platanias LC . AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 2010; 398: 135–139.

    Article  CAS  Google Scholar 

  32. ClinicalTrials.gov. Statin and prostate cancer. Available at: http://clinicaltrials.gov/ct2/results?term=statinandprostatecancer&Search=Search. Accessed 25 March 2014.

  33. ClinicalTrials.gov. Metformin and prostate cancer. Available at: http://clinicaltrials.gov/ct2/results?term=metforminandprostatecancer&Search=Search. Accessed 25 March 2014.

Download references

Acknowledgements

Disclaimer

No author has direct or indirect commercial financial incentive associated with publishing the article. All authors have read and approved the manuscript, which is not under consideration elsewhere.

Author information

Authors and Affiliations

  1. Department of Urology, Herbert Irving Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA,

    M R Danzig, S Kotamarti, R A Ghandour, M B Rothberg, B P Dubow, M C Benson, K K Badani & J M McKiernan

Authors
  1. M R Danzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Kotamarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R A Ghandour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M B Rothberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B P Dubow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M C Benson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K K Badani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J M McKiernan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Danzig.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Danzig, M., Kotamarti, S., Ghandour, R. et al. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis 18, 63–68 (2015). https://doi.org/10.1038/pcan.2014.47

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.47

This article is cited by

Search

Advanced search

Quick links